

## CONCLUSION

### Verification of the methodology

A test is only valid if the following criteria are fulfilled:

- a) The titre of the test suspension of at least  $10^8$  TCID50 /ml is sufficiently high to at least enable a titre reduction of 4 lg to verify the method.
- b) Detectable titre reduction is at least 4  $\log_{10}$ .
- c) Difference of the logarithmic titre of the virus control minus the logarithmic titre of the test virus in the reference inactivation test is between:
  - Between 0.75 and 3.5 after 5 min and between 2.0 and 4.0 after 15 min for Vaccinia virus
- d) Cytotoxicity of the product solution does not affect cell morphology and growth or susceptibility for the test virus in the dilutions of the test mixtures which are necessary to demonstrate a 4  $\log_{10}$  reduction of the virus.
- e) The interference control result does not show a difference of  $< 1.0 \log_{10}$  of virus titre for test product treated cells in comparison to the non-treated cells.
- e) Neutralisation validation. This is called the disinfectant suppression test in this protocol. The disinfectant was neutralised by column chromatography through an Illustra Microspin S-400 HR column to achieve the best possible neutralisation available for this test. The difference for virus is greater than 0.5  $\log_{10}$  indicating rapid irreversible virucidal activity of the disinfectant by dilution at a concentration of 25.0% v/v for VS1. This neutralisation validation has been verified by VS2, which shows the product has been successfully neutralised.

According to EN 14476:2013 + A2:2019, H&H 103C POSSESSES VIRUCIDAL activity at a concentration of 2.5% v/v as tested after 5 MINUTES at 20°C under CLEAN conditions (0.3 g/l bovine albumin) against Vaccinia virus VR-1549 Elstree strain /Vero cells.

The cytotoxicity of the product prevented a pass being observed at 25.0% v/v.

**This product therefore is effective against all enveloped viruses as defined in EN 14476:2013 + A2:2019 Annex A\*. This therefore includes all coronaviruses and SARS-CoV-2.**

Authorised signatory



Dr Chris Woodall, Director  
BluTest Laboratories Ltd  
Glasgow, UK.  
Date: 04 May 2020

### DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with an EN 14476 protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.